Single User License
INR 136040
Site License
INR 272080
Corporate User License
INR 408120

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Candidiasis-Pipeline Review, H1 2015

Candidiasis-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Candidiasis-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Candidiasis-Pipeline Review, H1 2015', provides an overview of the Candidiasis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Candidiasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Candidiasis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Candidiasis

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Candidiasis and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Candidiasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Candidiasis pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Candidiasis

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Candidiasis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 8

List of Figures 9

Introduction 10

Global Markets Direct Report Coverage 10

Candidiasis Overview 11

Therapeutics Development 12

Pipeline Products for Candidiasis-Overview 12

Pipeline Products for Candidiasis-Comparative Analysis 13

Candidiasis-Therapeutics under Development by Companies 14

Candidiasis-Therapeutics under Investigation by Universities/Institutes 17

Candidiasis-Pipeline Products Glance 18

Late Stage Products 18

Clinical Stage Products 19

Early Stage Products 20

Unknown Stage Products 21

Candidiasis-Products under Development by Companies 22

Candidiasis-Products under Investigation by Universities/Institutes 25

Candidiasis-Companies Involved in Therapeutics Development 26

Actavis plc 26

Aureogen Biosciences, Inc. 27

Basilea Pharmaceutica AG 28

Biomar Microbial Technologies 29

Cellceutix Corporation 30

Eisai Co., Ltd. 31

General Biologicals Corporation 32

Grupo Ferrer Internacional, S.A. 33

iCo Therapeutics Inc. 34

Novabiotics Ltd 35

NovaDigm Therapeutics, Inc. 36

Novartis AG 37

Onxeo SA 38

Panacela Labs, Inc. 39

Scynexis, Inc. 40

Sealife PHARMA GMBH 41

Sequella, Inc. 42

Viamet Pharmaceuticals, Inc. 43

Wellstat Vaccines, LLC 44

Candidiasis-Therapeutics Assessment 45

Assessment by Monotherapy Products 45

Assessment by Target 46

Assessment by Mechanism of Action 48

Assessment by Route of Administration 50

Assessment by Molecule Type 52

Drug Profiles 54

AC-17-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

albaconazole-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

amphotericin b-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

arasertaconazole-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

AUGC-10-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

AUGC-15-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

candida vaccine-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

candidiasis vaccine-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

E-1210-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

E-1211-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

isavuconazonium sulfate-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

miconazole-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

mutanobactins-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

NDV-3-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

NDV-3A-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

NP-339-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

PAC-113-Drug Profile 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

pegylated amphotericin B-Drug Profile 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

PEV-7-Drug Profile 77

Product Description 77

Mechanism of Action 77

R&D Progress 77

PMX-1408-Drug Profile 78

Product Description 78

Mechanism of Action 78

R&D Progress 78

PMX-1502-Drug Profile 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

PMX-1570-Drug Profile 80

Product Description 80

Mechanism of Action 80

R&D Progress 80

PMX-1576-Drug Profile 81

Product Description 81

Mechanism of Action 81

R&D Progress 81

PMX-1591-Drug Profile 82

Product Description 82

Mechanism of Action 82

R&D Progress 82

PMX-1625-Drug Profile 83

Product Description 83

Mechanism of Action 83

R&D Progress 83

PMX-30016-Drug Profile 84

Product Description 84

Mechanism of Action 84

R&D Progress 84

PMX-519-Drug Profile 85

Product Description 85

Mechanism of Action 85

R&D Progress 85

Prof-002-Drug Profile 86

Product Description 86

Mechanism of Action 86

R&D Progress 86

Recombinant Peptides for Oropharyngeal Candidiasis-Drug Profile 87

Product Description 87

Mechanism of Action 87

R&D Progress 87

SCY-078-Drug Profile 88

Product Description 88

Mechanism of Action 88

R&D Progress 88

SLP-0901-Drug Profile 90

Product Description 90

Mechanism of Action 90

R&D Progress 90

SLP-0904-Drug Profile 91

Product Description 91

Mechanism of Action 91

R&D Progress 91

Small Molecule for Candidiasis-Drug Profile 92

Product Description 92

Mechanism of Action 92

R&D Progress 92

Small Molecule for Candidiasis-Drug Profile 93

Product Description 93

Mechanism of Action 93

R&D Progress 93

Small Molecule for Candidiasis and Cryptococcosis-Drug Profile 94

Product Description 94

Mechanism of Action 94

R&D Progress 94

Small Molecule for Cryptococcosis and Candidiasis-Drug Profile 95

Product Description 95

Mechanism of Action 95

R&D Progress 95

Small Molecule for Fungal Infections-Drug Profile 96

Product Description 96

Mechanism of Action 96

R&D Progress 96

Small Molecules for Aspergillosis and Candidiasis-Drug Profile 97

Product Description 97

Mechanism of Action 97

R&D Progress 97

Small Molecules for Candidiasis-Drug Profile 98

Product Description 98

Mechanism of Action 98

R&D Progress 98

Small Molecules for Candidiasis-Drug Profile 99

Product Description 99

Mechanism of Action 99

R&D Progress 99

Small Molecules for Fungal Infections-Drug Profile 100

Product Description 100

Mechanism of Action 100

R&D Progress 100

SQ-109-Drug Profile 101

Product Description 101

Mechanism of Action 101

R&D Progress 101

VT-1161-Drug Profile 104

Product Description 104

Mechanism of Action 104

R&D Progress 104

XELRYX-3-Drug Profile 106

Product Description 106

Mechanism of Action 106

R&D Progress 106

Candidiasis-Recent Pipeline Updates 108

Candidiasis-Dormant Projects 122

Candidiasis-Discontinued Products 125

Candidiasis-Product Development Milestones 126

Featured News & Press Releases 126

Nov 03, 2014: Basilea Reports Granting Of U.S. Orphan Drug Designation To Isavuconazole For The Treatment Of Invasive Candidiasis 126

Oct 16, 2014: Basilea Reports Protocol Amendment Resulting In Earlier Completion Of Isavuconazole Phase 3 Invasive Candidiasis Study 126

Sep 10, 2014: Data for Viamet's VT-1161 Presented at ICAAC 2014 127

Jul 16, 2014: FDA Grants Astellas Qualified Infectious Disease Product Designation for Isavuconazole for the Treatment of Invasive Candidiasis 128

Jul 10, 2014: Viamet Reports Additional Positive Interim Results of Phase 2 Study of VT-1161 in Patients with Moderate to Severe Acute Vulvovaginal Candidiasis 128

Apr 01, 2014: BioAlliance Pharma provides an update on its partnerships for Loramyc/Oravig 129

Feb 18, 2014: Viamet Reports Positive Interim Results of Phase 2 Study of VT-1161 130

Nov 18, 2013: Cellceutix Identifies PMX-1408 as treatment Gram-Negative and Candida Fungal Infections 130

Nov 18, 2013: Cellceutix Identifies Drug Candidate for Candida Fungal Infections 131

Sep 26, 2013: NovaDigm Therapeutics Initiates Phase 1b/2a Clinical Trial with NDV-3 Vaccine in Recurrent Vulvovaginal Candidiasis 132

Appendix 134

Methodology 134

Coverage 134

Secondary Research 134

Primary Research 134

Expert Panel Validation 134

Contact Us 135

Disclaimer 135

List of Tables

Number of Products under Development for Candidiasis, H1 2015 12

Number of Products under Development for Candidiasis-Comparative Analysis, H1 2015 13

Number of Products under Development by Companies, H1 2015 15

Number of Products under Development by Companies, H1 2015 (Contd..1) 16

Number of Products under Investigation by Universities/Institutes, H1 2015 17

Comparative Analysis by Late Stage Development, H1 2015 18

Comparative Analysis by Clinical Stage Development, H1 2015 19

Comparative Analysis by Early Stage Development, H1 2015 20

Comparative Analysis by Unknown Stage Development, H1 2015 21

Products under Development by Companies, H1 2015 22

Products under Development by Companies, H1 2015 (Contd..1) 23

Products under Development by Companies, H1 2015 (Contd..2) 24

Products under Investigation by Universities/Institutes, H1 2015 25

Candidiasis-Pipeline by Actavis plc, H1 2015 26

Candidiasis-Pipeline by Aureogen Biosciences, Inc., H1 2015 27

Candidiasis-Pipeline by Basilea Pharmaceutica AG, H1 2015 28

Candidiasis-Pipeline by Biomar Microbial Technologies, H1 2015 29

Candidiasis-Pipeline by Cellceutix Corporation, H1 2015 30

Candidiasis-Pipeline by Eisai Co., Ltd., H1 2015 31

Candidiasis-Pipeline by General Biologicals Corporation, H1 2015 32

Candidiasis-Pipeline by Grupo Ferrer Internacional, S.A., H1 2015 33

Candidiasis-Pipeline by iCo Therapeutics Inc., H1 2015 34

Candidiasis-Pipeline by Novabiotics Ltd, H1 2015 35

Candidiasis-Pipeline by NovaDigm Therapeutics, Inc., H1 2015 36

Candidiasis-Pipeline by Novartis AG, H1 2015 37

Candidiasis-Pipeline by Onxeo SA, H1 2015 38

Candidiasis-Pipeline by Panacela Labs, Inc., H1 2015 39

Candidiasis-Pipeline by Scynexis, Inc., H1 2015 40

Candidiasis-Pipeline by Sealife PHARMA GMBH, H1 2015 41

Candidiasis-Pipeline by Sequella, Inc., H1 2015 42

Candidiasis-Pipeline by Viamet Pharmaceuticals, Inc., H1 2015 43

Candidiasis-Pipeline by Wellstat Vaccines, LLC, H1 2015 44

Assessment by Monotherapy Products, H1 2015 45

Number of Products by Stage and Target, H1 2015 47

Number of Products by Stage and Mechanism of Action, H1 2015 49

Number of Products by Stage and Route of Administration, H1 2015 51

Number of Products by Stage and Molecule Type, H1 2015 53

Candidiasis Therapeutics-Recent Pipeline Updates, H1 2015 108

Candidiasis-Dormant Projects, H1 2015 122

Candidiasis-Dormant Projects (Contd..1), H1 2015 123

Candidiasis-Dormant Projects (Contd..2), H1 2015 124

Candidiasis-Discontinued Products, H1 2015 125

List of Figures

Number of Products under Development for Candidiasis, H1 2015 12

Number of Products under Development for Candidiasis-Comparative Analysis, H1 2015 13

Number of Products under Development by Companies, H1 2015 14

Number of Products under Investigation by Universities/Institutes, H1 2015 17

Comparative Analysis by Clinical Stage Development, H1 2015 19

Comparative Analysis by Early Stage Products, H1 2015 20

Assessment by Monotherapy Products, H1 2015 45

Number of Products by Top 10 Targets, H1 2015 46

Number of Products by Stage and Top 10 Targets, H1 2015 47

Number of Products by Top 10 Mechanism of Actions, H1 2015 48

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 49

Number of Products by Top 10 Routes of Administration, H1 2015 50

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 51

Number of Products by Top 10 Molecule Types, H1 2015 52

Number of Products by Stage and Top 10 Molecule Types, H1 2015 53

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Actavis plc

Aureogen Biosciences, Inc.

Basilea Pharmaceutica AG

Biomar Microbial Technologies

Cellceutix Corporation

Eisai Co., Ltd.

General Biologicals Corporation

Grupo Ferrer Internacional, S.A.

iCo Therapeutics Inc.

Novabiotics Ltd

NovaDigm Therapeutics, Inc.

Novartis AG

Onxeo SA

Panacela Labs, Inc.

Scynexis, Inc.

Sealife PHARMA GMBH

Sequella, Inc.

Viamet Pharmaceuticals, Inc.

Wellstat Vaccines, LLC

Candidiasis Therapeutic Products under Development, Key Players in Candidiasis Therapeutics, Candidiasis Pipeline Overview, Candidiasis Pipeline, Candidiasis Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com